Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2024 Annual Meeting | C105 - Alzheimer's Disease

Tuesday 04/16/24
07:00 AM - 09:00 AM MDT Add To Calendar
Colorado Convention Center | Four Seasons 4
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Liliana A. Ramirez-Gomez, MD
Aging, Dementia, Cognitive, and Behavioral Neurology
During this course, participants will be introduced to the concept of AD as a clinicopathologic entity and explain approaches to detect AD early in the disease continuum; discuss the range of biomarker breakthroughs to detect AD, including blood base, CSF, and neuroimaging biomarkers, and the role of these tools in research and clinical practice; discuss the importance of integrating clinical assessment and biomarkers to obtain an early diagnosis; recognize and understand the clinical heterogeneity in AD; discuss the most recent therapeutic advances and emerging therapies for Alzheimer's disease and discuss the Appropriate Use Recommendations for monoclonal antibodies and its implementation in clinical practice.
 
This program is supported in part by educational grants from Lilly and Eisai Inc.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Introductory
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator
Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM MDT Introduction Welcome and Introductions
Liliana A. Ramirez-Gomez, MD
07:05 AM - 07:40 AM MDT Speaker The Use of Biomarkers for the Diagnosis and Staging of Alzheimer’s Disease
Julio C. Rojas-Martinez, MD, PhD
07:40 AM - 08:10 AM MDT Speaker Emerging Therapies for the Treatment of Alzheimer’s Disease
Jeremy J. Pruzin, MD
08:10 AM - 08:40 AM MDT Speaker Implementation of Newly Approved Disease-modifying Therapies for Alzheimer’s Disease in Clinical Practice
Liliana A. Ramirez-Gomez, MD
08:40 AM - 09:00 AM MDT Discussion Questions & Answers
Julio C. Rojas-Martinez, MD, PhD, Liliana A. Ramirez-Gomez, MD, Jeremy J. Pruzin, MD
Faculty Disclosures
Liliana A. Ramirez-Gomez, MD The institution of Dr. Ramirez-Gomez has received research support from NIA-NIH.
Jeremy J. Pruzin, MD Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from Alzheimer's Association. The institution of Dr. Pruzin has received research support from NIA.
Julio C. Rojas-Martinez, MD, PhD The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. Dr. Rojas-Martinez has received research support from Roon, Healthcare. The institution of Dr. Rojas-Martinez has received research support from Amylyx.